Working in mice, Alexander Levitzki and colleagues (of The Hebrew University of Jerusalem and Ludwig-Maximilians-University in Munich) took advantage of previous research that showed how to distinguish between cancerous and healthy cells through the detection of molecules known as epidermal growth factor receptors (EGFR). The glioblastoma cells overexpress EGFR (that is, in comparison with normal brain cells, they have many more of these molecules on their surface). The scientists then selected a type of genetic material (a nucleic acid) associated with viral infections and linked it to a compound that could bind to EGFR. As a result of the defence mechanisms that have evolved to protect mammalian cells from viruses, cells are programmed to die once they take up this particular nucleic acid. The treatment therefore eliminates the tumor cells but avoids damage to the normal brain tissue.
The researchers found that the treatment was effective in mice implanted with human brain tumor cells that overexpressed EGFR. The treatment could eliminate established cancers and there was no evidence of recurrence: the mice remained cancer free for over a year. It is more difficult to cure cancer in humans than cancer in mice, but the results are encouraging. In his Perspective article accompanying the study, Robert Weil of the Brain Tumor Institute at the Cleveland Clinic Foundation suggests that the approach deserves to be "fast-tracked to the clinic" given the lack of effective treatments for GBM. There are few existing options aside from chemotherapy and surgery to remove the tumor, and it is rare that these treatments stop the cancer from recurring. Given the prevalence of EGFR in cells of other cancer types (such as breast cancer and lung cancer), the approach pioneered in this study may be applicable to other forms of cancer as well.
Citation: Shir A, Ogris M, Wagner E, Levitzki A (2006) EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med 3(1): e6.
On the related Perspective article: Citation: Weil RJ (2006) Glioblastoma multiforme--Treating a deadly tumor with both strands of RNA. PLoS Med 3(1): e31.
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-01-weil.pdf
CONTACT:
Alexander Levitzki
The Institute for Advanced Studies
The Hebrew University of Jerusalem
Jerusalem, Israel 91904
+972-2-6585-404
+972-2-6512-958 (fax)
levitzki@vms.huji.ac.il
PLEASE MENTION PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES. THANK YOU.
All works published in PLoS Medicine are open access. Everything is immediately available--to read, download, redistribute, include in databases, and otherwise use-- without cost to anyone, anywhere subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org
Journal
PLoS Medicine